Abstract: μ-opioid receptor (MOR) agonists such as morphine are powerful analgesics used for pain therapy. However, the use of these drugs is limited by their side-effects, which include antinociceptive tolerance and dependence. Earlier studies reported that MOR analgesic tolerance is reduced by blockade of δ-opioid receptors (DORs) that interact with MORs. Recent studies show that the MOR/DOR interaction in nociceptive afferent neurons in the dorsal root ganglion may contribute to morphine analgesic tolerance. Further analysis of the mechanisms for regulating the trafficking of receptors, ion channels and signaling molecules in nociceptive afferent neurons would help to understand the nociceptive mechanisms and improve pain therapy.
Introduction
Small-diameter neurons in the dorsal root ganglia (DRGs) convey signals from nociceptors, thermoreceptors and sensitive mechanoreceptors to the dorsal horn of the spinal cord through afferent Aδ-and C-fibers that terminate in laminae I and II. In response to peripheral noxious stimulation, the excitatory neurotransmitter glutamate is released from these afferent terminals in the superficial dorsal horn. Studies over the past decades showed that this excitatory neurotransmission is negatively regulated by inhibitory regulators released from local neurons, such as opioid peptides acting on the presynaptic μ-and δ-opioid receptors (MORs and DORs). Accumulating evidence suggests that the DOR/MOR interaction in nociceptive afferent neurons is a mechanism for morphine analgesic tolerance. In the present review, we summarize the recent studies on the expression and interaction of opioid receptors in primary sensory neurons and their functional impact on pain modulation, and discuss their potential roles in the pain therapy.
Expression of opioid receptors in nociceptive afferent neurons
Autoradiographic studies provide evidence showing the presence of opioid receptors in afferent Aδ-and Cfibers in laminae I and II of the spinal cord, including the binding sites for DOR and MOR agonists [1] [2] [3] [4] [5] . The presence of DORs on nociceptive afferents is supported by findings that release of the excitatory neurotransmitters glutamate, substance P and calcitonin gene-related peptide (CGRP)
from afferent C-and Aδ-fibers is inhibited by the activa-tion of DORs [6, 7] . These early findings suggested the presence of DORs on nociceptive afferent neurons, including the peptidergic subset of small DRG neurons.
Following the cloning of opioid receptor genes, DOR1
mRNA is found in ~70% of DRG neurons, including both peptidergic [isolectin B4 (IB4)-negative] and non-peptidergic (IB4-positive) subsets of small neurons and large neurons, while MOR1 mRNA is mainly present in peptidergic small neurons [8] [9] [10] [11] [12] . DOR-mediated spinal analgesia is attenuated
by the intrathecally applied antisense oligodeoxynucleotide of the DOR1 gene (Oprd1), and the deletion of Oprd1 or the preproenkephalin gene (Penk1) [13] [14] [15] .
Endogenous DORs can be detected specifically by immunoblotting with DOR antibodies, including commercially available antibodies, in the DRGs and the dorsal spinal cord of wild-type but not DOR-deficient mice [10, 11, 15, 16] .
However, the proper dilutions of the same antibodies are required to immunostain DORs specifically in the DRGs and laminae I and II [10] . This is an example for testing the specificity of receptor antibodies, though it is well-known that all antibodies must be used at appropriate concentrations for specific immunoblotting and immunostaining in various tissues. So far, no antibodies are available to simultaneously stain the endogenous DORs in all subsets of DRG neurons and their afferent terminals. Individual antibodies can be used to immunostain DORs in peptidergic small DRG neurons and large DRG neurons but not DORs expressed in IB4-positive small DRG neurons [10, 17] .
It is possible that the antibodies recognize DORs in different states of activation, conformation, glycosylation and/ or palmitoylation [18] [19] [20] [21] . To exclude the possibility of nonspecific immunostaining [22] , it is important to carefully assess the antibody specificity and comprehensively analyze the distribution of DORs with multiple experimental approaches [10] .
Based on the findings of DOR-and MOR-mediated inhibitory effects on both the Ca 2+ currents in small DRG neurons and the release of substance P from C-and Aδ-afferents, as well as the results of immunostaining [7, 16, 17, [23] [24] [25] [26] [27] [28] [29] , DORs and MORs are suggested to be co-expressed in peptidergic small DRG neurons. However, a study in the mouse expressing DOR with insertion of enhanced green fluorescent protein (eGFP) at the C-terminus showed that only ~17% of DRG neurons are immunostained for DOReGFP [22] . Besides, most of these immunostained neurons are large and NF200-positive, while DOR-eGFP is rarely detected in peptidergic small DRG neurons that express
MORs. In the dorsal spinal cord, the DOR-eGFP-positive structures overlap with PKCγ-expressing neurons in inner lamina II [22] . Nevertheless, it remains unclear whether these eGFP-positive structures are Aβ-afferents from the DOR-eGFP-expressing large DRG neurons or IB4-positive C-afferents, or due to ectopic expression of eGFP in local neurons. In fact, the mechanosensitive Aβ-afferents of large DRG neurons primarily project to spinal laminae III and IV in rodents [30] .
To evaluate these conflicting results, several labora- . Importantly, using antibodies that recognize DOR/MOR heteromers, Gupta et al. [34] were able to demonstrate the presence of the opioid receptor heteromer in DRG neurons. Thus, DORs and
MORs are co-expressed in a considerable population of peptidergic small DRG neurons, and form heteromers that are involved in pain modulation [35] [36] [37] .
Regulation of the plasma membrane insertion of opioid receptors
In both peptidergic small DRG neurons and PC12 [26, 33, 34, 38, [48] [49] [50] [51] .
In peptidergic small DRG neurons and PC12 cells,
both endogenous MORs and exogenously expressed tagged
MORs can be inserted into the plasma membrane without stimulation [10, 25, 41] . Therefore, the interaction between
MORs and DORs could be enhanced by stimuli that induce the membrane insertion of DORs, although opioid receptor heteromers could also be present in the cytoplasm [34] . In large DRG neurons that do not contain neuropeptides and LDCVs, immunostaining of DORs can be present on the surface of cell bodies, but is mostly absent from their afferent terminals in spinal laminae III and IV, consistent with the receptor autoradiographic results [10, 22, 52] . It remains largely unknown why the DORs expressed in large DRG neurons cannot be efficiently transported to the terminals of Aβ-afferent fibers in the deep laminae of the spinal cord.
Using liquid chromatography-mass spectrometry combined with immunoblotting of subcellular fractions, Zhao et al. [39] [53] [54] [55] [56] [57] [58] . In addition, DORs and MORs may interact with β 2 -and α 2A -adrenergic receptors that are expressed in DRG neurons, respectively [39, [59] [60] [61] . Although the functional consequences of the stimulus-induced coinsertion of LDCV-associated molecules remain largely unclear, one could expect that such a reaction would cause a "phenotypic" modification of the plasma membrane, enabling a shift of the sensitivity of nociceptive afferent neurons to many neurotransmitters, neuromodulators and applied drugs.
In the nervous system, DORs expressed in different types of neurons may have subcellular distribution patterns distinct from that in DRG neurons. Moreover, only 40% of DORs expressed in transfected HEK cells are transported to the cell surface, while the rest are retained in the endoplasmic reticulum [62] . Such intracellular retention of DORs may also be present in many neurons. It would be interesting to reveal the mechanisms for retaining DORs intracellularly and releasing these receptors from the retention pool.
Although cell biological analysis of the mechanisms of DOR trafficking in the brain is very limited, several studies
showed that nerve growth factor triggers the cell surface expression of DORs, and DOR activation can induce the plasma membrane insertion of GABA A receptors [63, 64] . 
afferent neurons
Given that co-expression of DORs and MORs in peptidergic small DRG neurons could be a cellular basis for opioid receptor interaction in the pain pathway [10, 11, 27, 29, [31] [32] [33] [34] , the functional analysis of MOR/DOR heteromers would be critical for understanding opioid physiology and pharmacology [35] [36] [37] . Recent studies show that treatment with either DOR agonists or the MOR agonist Tyr-D-AlaGly-MePhe-Gly-ol (DAMGO) and methadone but not morphine results in endocytosis of DOR/MOR heteromers in transfected HEK293 cells [11, 65] . The receptor complexes internalized by DOR agonists are ubiquitinated for lysosomal degradation, leading to a reduction of surface MORs [11] . In addition, a basal level of co-internalization and co-degradation of DORs and MORs occurs in the transfected cells [11, 65] . The mechanism of such a reaction in the cells remains unknown. However, the basal level of co-degradation of MOR/DOR heteromers in the spinal cord may be caused by opioid peptide enkephalin released from dorsal horn neurons [11, 66] . The co-degradation of these opioid receptors is enhanced by treatment with exogenously applied DOR agonists [11] or persistent release of endogenous opioid peptides with a high affinity for DORs. It is interesting that DOR antagonists attenuate the methadoneinduced co-internalization of MOR/DOR heteromers in transfected HEK293 cells [65] . MOR/DOR heteromers could recruit β-arrestin, while DORs but not MORs are normally coupled with β-arrestin [67, 68] . Taken together, the interaction between DORs and MORs plays an important role in regulating receptor trafficking, signaling, functioning and metabolism, and is involved in the mechanisms of pain modulation and brain disorders [35] [36] [37] [69] [70] [71] .
Both MORs and DORs have been known for decades
to inhibit nociceptive transmission in the spinal cord.
However, a study published in 2009 suggested that DORs and MORs function in segregated spinal sensory circuits mediating the inhibitory effect on mechanical or thermal hyperalgesia respectively, due to the absence of DOReGFP in the MOR-expressing peptidergic small DRG neurons and the presence of DOR-eGFP in large DRG neurons [22] . However, during the past two years, many studies have demonstrated that DOR agonists and MOR agonists induce analgesic effects on both thermal and mechanical hyperalgesia through activating these opioid receptors co-expressed in nociceptive afferent neurons [11, 12, 31, 33, 72] , attenuated by a MOR antagonist [79] . However, after treatment with the TRP agonist icilin, the presynaptic inhibition induced by the DOR agonist increases and is blocked by the DOR antagonist [79] , suggesting that the TRP agonistinduced surface expression of DORs is important for producing a DOR-selective inhibitory effect. Therefore, the ratio of DOR versus MOR in the plasma membrane and the formation of DOR/MOR heteromers appear to be important factors that regulate the pharmacological properties of opioid ligands in vivo.
Contribution of opioid receptor interaction to the mechanism of morphine antinociceptive tolerance
Opioid analgesics (e.g. morphine) with high affinity for MORs are still the most powerful analgesics available for pain relief. However, their chronic use may lead to the development of antinociceptive tolerance and dependence [80] [81] [82] . Early pharmacological studies showed that blockade of DORs often results in enhanced morphine analgesia and reduced tolerance [83] [84] [85] [86] , suggesting that DORs interact with MORs in the pain pathway [87] [88] [89] [90] . Further studies revealed that morphine tolerance can be reduced by preventing DOR phosphorylation, deleting either Oprd1 or Penk1, or deleting Tac1 that reduces DOR transport to the spinal dorsal horn via LDCVs [14, 15, 17, 91] .
A recent study showed that the DOR agonist-induced teract with these opioid receptors [39] (see also references 37 and 92). Moreover, it would be interesting to further study the regulatory mechanisms for post-endocytic trafficking of the MOR/DOR heteromers, including mechanisms for degradation and recycling, following different MOR agonists such as DAMGO, methadone and other opioid analgesics [11, 65, [93] [94] [95] .
Conclusion
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